<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723694</url>
  </required_header>
  <id_info>
    <org_study_id>7665</org_study_id>
    <nct_id>NCT03723694</nct_id>
  </id_info>
  <brief_title>Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders</brief_title>
  <official_title>Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the effect of a cocoa-derived dietary flavanol on brain structures and cognitive&#xD;
      outcomes in a 12-week randomized controlled trial of 146 healthy participants, age 50-69, who&#xD;
      will receive this cocoa derivative or a placebo. We also will examine the role of&#xD;
      inflammation in this relationship.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within 25 years, the US population aged 65 and over will double in size to 80 million&#xD;
      bringing, with it an epidemic of aging-related cognitive decline, from normal cognitive aging&#xD;
      to neurodegenerative disorders including Alzheimer's Disease. These conditions impair quality&#xD;
      of life and functional status, impose an enormous burden on individuals, their families, the&#xD;
      healthcare system, and require elucidation of mechanisms and development of new treatments to&#xD;
      prevent or at least slow their progression. The use of plant-based food and drink for health&#xD;
      purposes has a long and well-documented history. Cocoa beans contain a substance that has&#xD;
      multiple beneficial health effects. In this study, the investigators will test the effect of&#xD;
      this substance on brain structures and cognitive outcomes in a 12-week randomized controlled&#xD;
      trial of 146 healthy participants, age 50-69, who will receive this cocoa derivative or a&#xD;
      placebo. The investigators also will examine the role of inflammation in this relationship.&#xD;
      Such a trial has potential for significant clinical impact.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HMGB1</measure>
    <time_frame>12 weeks</time_frame>
    <description>circulating levels of the inflammatory marker HMGB1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NFkB</measure>
    <time_frame>12 weeks</time_frame>
    <description>TLR4-dependent NFkB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNFa</measure>
    <time_frame>12 weeks</time_frame>
    <description>TLR4-dependent TNFa</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ModBent</measure>
    <time_frame>12 weeks</time_frame>
    <description>modified Benton Recognition Task</description>
  </other_outcome>
  <other_outcome>
    <measure>ModRey</measure>
    <time_frame>12 weeks</time_frame>
    <description>Modified Rey Auditory Verbal Learning Test</description>
  </other_outcome>
  <other_outcome>
    <measure>multiple cognitive domains</measure>
    <time_frame>12 weeks</time_frame>
    <description>NIH Toolbox Cognition Battery, which includes adaptive computerized tests of executive function, attention, episodic memory, language, processing speed, and working memory</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Memory Loss</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>650 mg of Cocoapro flavanols</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0mg Cocoapro flavanols</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>650 mg of Cocoapro flavanols</intervention_name>
    <description>12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.</description>
    <arm_group_label>650 mg of Cocoapro flavanols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>0 mg of Cocoapro flavanols</intervention_name>
    <description>12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.</description>
    <arm_group_label>0mg Cocoapro flavanols</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent obtained before any trial-related activities.&#xD;
             (Trial-related activities are any procedure that would not have been performed during&#xD;
             normal screening or management of the subject).&#xD;
&#xD;
          2. Healthy Male or Female subjects. (Females must be post-menopausal)&#xD;
&#xD;
          3. Age between 50 and 69 years, both inclusive.&#xD;
&#xD;
          4. Body mass index between 18.0 and 35 kg/mÂ², both inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently undergoing medical treatment, including prescription drugs/medication.&#xD;
&#xD;
          2. Clinically significant abnormal hematology, biochemistry, urinalysis, or coagulation&#xD;
             screening tests, as judged by the Investigator.&#xD;
&#xD;
          3. History or presence of cancer (except basal cell skin cancer or squamous cell skin&#xD;
             cancer), or any clinically significant cardiovascular, respiratory, metabolic, renal,&#xD;
             hepatic, gastrointestinal, endocrinological (with the exception euthyroid struma),&#xD;
             haematological, dermatological, venereal, neurological, psychiatric diseases or other&#xD;
             major disorders as judged by the Investigator.&#xD;
&#xD;
          4. Seated blood pressure at screening (after resting for 5 min in seated position)&#xD;
             outside the range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic (excluding&#xD;
             white-coat hypertension; therefore, if a repeated measurement shows values within the&#xD;
             range, the subject can be included in the trial) and/or resting supine heart rate&#xD;
             outside the range 50-90 beats per minute. Measurement taken at consent before&#xD;
             eligibility is determined&#xD;
&#xD;
          5. Heart Diseases.&#xD;
&#xD;
          6. Hepatitis B or C positive status.&#xD;
&#xD;
          7. HIV positive status.&#xD;
&#xD;
          8. History of multiple and/or severe allergies to drugs or foods or a history of severe&#xD;
             anaphylactic reaction.&#xD;
&#xD;
          9. Use of non-prescription medication, herbal products or nutritional supplements during&#xD;
             the study, and within the last 4 weeks before the start of the study (screening), as&#xD;
             judged by the Investigator; occasional use of aspirin, ibuprofen, acetaminophen is&#xD;
             permitted.&#xD;
&#xD;
         10. Adherence to a vegan or vegetarian diet or to specialty/uncommon diets.&#xD;
&#xD;
         11. Food Allergies to tree nuts, soy, cocoa and cocoa-containing products.&#xD;
&#xD;
         12. People who choose to avoid caffeine intake.&#xD;
&#xD;
         13. Current or history of alcoholism or drug/chemical abuse as per Investigator's&#xD;
             judgment.&#xD;
&#xD;
         14. Hormone Replacement Therapy; Currently pregnant; Pregnant or Interview\ lactating&#xD;
             within past 6 months; Hormonal birth control (pill).&#xD;
&#xD;
         15. Smoking.&#xD;
&#xD;
         16. Unwilling to have blood drawn or anxiety/nausea during a blood draw.&#xD;
&#xD;
         17. Uncomfortable completing memory and attention tasks in the English language&#xD;
&#xD;
         18. Montreal Cognitive Assessment (MoCA) score less than 26.&#xD;
&#xD;
         19. Inability to swallow study capsules Interview (at Consent)&#xD;
&#xD;
         20. Did not complete the two weeks Run-In Period (Participants who missed more than 2&#xD;
             intake occasions out of 14 days (28 occasions total) or if there are &gt; 8 capsules left&#xD;
             in the bottle after the two weeks will be excluded).&#xD;
&#xD;
        MRI RELATED&#xD;
&#xD;
          1. Cardiac Pacemaker&#xD;
&#xD;
          2. Internal Pump&#xD;
&#xD;
          3. Insulin Pump&#xD;
&#xD;
          4. Tattoo eyeliner&#xD;
&#xD;
          5. Wire sutures&#xD;
&#xD;
          6. Internal Metal Objects&#xD;
&#xD;
          7. Metal Slivers in Eye&#xD;
&#xD;
          8. Prosthesis&#xD;
&#xD;
          9. Hearing Aid Implants&#xD;
&#xD;
         10. Neurostimulator&#xD;
&#xD;
         11. Metal Fragments&#xD;
&#xD;
         12. Brain Aneurysm Clips&#xD;
&#xD;
         13. Vascular Clips&#xD;
&#xD;
         14. Breast Expander&#xD;
&#xD;
         15. Vena Cava Filter&#xD;
&#xD;
         16. Heart Valve&#xD;
&#xD;
         17. Metal Stents&#xD;
&#xD;
         18. Asthmatic symptoms within the past 3 years&#xD;
&#xD;
         19. Sickle Cell Disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Sloan, PhD</last_name>
      <phone>646-774-8940</phone>
      <email>rps7@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Richard Sloan, PhD</last_name>
      <phone>6467748940</phone>
      <email>rps7@columbia.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brickman AM, Khan UA, Provenzano FA, Yeung LK, Suzuki W, Schroeter H, Wall M, Sloan RP, Small SA. Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. Nat Neurosci. 2014 Dec;17(12):1798-803. doi: 10.1038/nn.3850. Epub 2014 Oct 26.</citation>
    <PMID>25344629</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Richard Sloan</investigator_full_name>
    <investigator_title>Nathaniel Wharton Professor of Behavioral Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03723694/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

